Drug Profile
ID 93
Alternative Names: ID 93/AP10-602; ID-93/GLA-SE; ID93 + AP10-602; ID93 + GLA-SE; Tuberculosis vaccine adjuvanted - Aeras/Infectious Disease Research Institute; Tuberculosis vaccine recombinant Mycobacterium tuberculosis protein ID93/adjuvant GLA-SE - Aeras/IDRI; Tuberculosis-vaccine-ID93-Aeras/Infectious-Disease-Research-Institute; Tuberculosis-vaccine-recombinant-Mycobacterium-tuberculosis-protein-ID93-Aeras/IDRILatest Information Update: 09 Mar 2023
Price :
$50
*
At a glance
- Originator Infectious Disease Research Institute
- Developer Aeras; Infectious Disease Research Institute; National Institutes of Health; Quratis
- Class Adjuvants; Recombinant fusion proteins; Synthetic vaccines; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Tuberculosis
Most Recent Events
- 07 Mar 2023 ID 93 is still in phase I trials for Tuberculosis (Prevention)in USA (IM, Injection)
- 07 Mar 2023 Immunogenicity data from a phase I trial in Tuberculosis released by Access to Advanced Health Institute (AAHI)
- 28 May 2022 No recent reports of development identified for phase-I development in Tuberculosis(In adolescents, Prevention) in South Korea (IM, Injection)